Unbound MEDLINE

Reactivation of Human Brain Homogenate Cholinesterases Inhibited by Tabun using Newly Developed Oximes K117 and K127. Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] Journal article

 
TitleReactivation of Human Brain Homogenate Cholinesterases Inhibited by Tabun using Newly Developed Oximes K117 and K127.
Author(s)Kuca K, Cabal J, Jung YS, Musilek K, Soukup O, Jun D, Pohanka M, Musilova L, Karasová J, Novotný L, Hrabinova M 
InstitutionCenter of Advanced Studies, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic.
SourceBasic Clin Pharmacol Toxicol 2009 May 15.
AbstractNewly developed acetylcholinesterase reactivators K117 [1,5-bis(4-hydroxyiminomethylpyridinium)-3-oxapentane dichloride] and K127 [(1-(4-hydroxyiminomethylpyridinium)-5-(4-carbamoylpyridinium)-3-oxapentane dibromide)] were tested for their potency to reactivate tabun-inhibited human brain cholinesterases. Pralidoxime and trimedoxime were chosen as standard reference reactivators. Human tissue was used, as that was closer on the real treatment of human beings. As a result, oxime K127 was found as the best tested reactivator according to the constant k(r), characterizing the overall reactivation process. On the contrary, the maximal reactivation ability expressed as percentage of reactivation was the best for trimedoxime. This differences were caused as a result of using the enzyme from different species. Due to this, experiments on human tissue should be conducted after in vitro and in vivo tests on animals to eliminate such important failures of promising oximes.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19473310
  
Advertise on this site.